Physician profile
Devanshi Jani
NPI 1770794083
$1,059.89
in general payments reported to CMS, 2019-2025
10 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $229 · 2021: $223 · 2022: $220 · 2023: $48.08 · 2024: $14.16 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $344.17 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $227.11 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $161.17 | 2020-2025 | Spravato |
| Lundbeck LLC | $114.96 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.56 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.28 | 2023-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $33.23 | 2020 | |
| Neurocrine Biosciences, INC. | $19.96 | 2023 | Ingrezza |
| Abbvie INC. | $14.80 | 2021 | |
| Merck Sharp & Dohme LLC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devanshi Jani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.